ライフサイエンスコーパス: cardiovascular risk

1 aging techniques and their relationship with cardiovascular risk.

2 scular dysfunction associated with increased cardiovascular risk.

3 their functional status, renal function, and cardiovascular risk.

4 ow to moderate glucocorticoid dose increases cardiovascular risk.

5 nts in a cohort of older individuals at high cardiovascular risk.

6 idence in some estimates for patients at low cardiovascular risk.

7 vels are elevated in patients with increased cardiovascular risk.

8 ts with elevated triglycerides and increased cardiovascular risk.

9 C1) have been associated with depression and cardiovascular risk.

10 diovascular disease who were at intermediate cardiovascular risk.

11 (EPA) and docosahexaenoic acid (DHA) reduce cardiovascular risk.

12 placebo were consistent across the range of cardiovascular risk.

13 erations, particularly in patients at a high cardiovascular risk.

14 fects varied across the spectrum of baseline cardiovascular risk.

15 ownership has been associated with decreased cardiovascular risk.

16 e kidney disease and is associated with high cardiovascular risk.

17 ex-stratified Cox models were used to assess cardiovascular risk.

18 quality have been associated with increased cardiovascular risk.

19 Type 2 diabetes is associated with increased cardiovascular risk.

20 obal assays and is a strong marker of future cardiovascular risk.

21 e unproven, off-label indication of reducing cardiovascular risk.

22 despite antiplatelet therapy, remain at high cardiovascular risk.

23 sentangle the relationship between Lp(a) and cardiovascular risk.

24 leviate symptoms and to potentially decrease cardiovascular risk.

25 lic blood pressure was associated with lower cardiovascular risk.

26 nd its manifestations in individuals at high cardiovascular risk.

27 formed prior to noncardiac surgery to assess cardiovascular risk.

28 endent parameter rather than a surrogate for cardiovascular risk.

29 a cardiovascular parameter applied to detect cardiovascular risk.

30 ing the link between mutations and increased cardiovascular risk.

31 een treatments in drug-naive patients at low cardiovascular risk.

32 dial adipose tissue (EAT) is associated with cardiovascular risk.

33 atherogenic lipoproteins in PLHIV with high cardiovascular risk.

34 ng cardiovascular events in patients at high cardiovascular risk.

35 basis of 12 clinical factors associated with cardiovascular risk.

36 veloping immune-based therapies for lowering cardiovascular risk.

37 tween marijuana and a broad range of adverse cardiovascular risks.

38 g for lipid disorders to reduce their future cardiovascular risks.

39 ndividuals with intermediate atherosclerotic cardiovascular risk according to standard risk predictio

40 Among patients with COPD and increased cardiovascular risk, aclidinium was noninferior to place

41 CAC has been shown to effectively stratify cardiovascular risk across ethnicities irrespective of a

42 Cardiovascular risk after HDP is largely but incompletel

43 derly patients are at particularly increased cardiovascular risk after myocardial infarction, but few

44 btained from patients who are homozygous for cardiovascular-risk alleles (R/R cardiomyocytes) or from

45 eshold >=140/90 mm Hg), or predicted 10-year cardiovascular risk alone (QRISK2 score >=10%).

46 3 years) with mild hypertension and with low cardiovascular risk and 24 healthy participants (15 men

47 Diabetes is associated with increased cardiovascular risk and higher occurrence of infections.

48 Inconsistent definitions of cardiovascular risk and low-level confidence in some est

49 triglyceridemia is associated with increased cardiovascular risk and may be caused by impaired lipopr

50 pendent and additive joint associations with cardiovascular risk and may be useful concurrently for g

51 However, adverse cardiovascular risk and negative fertility impacts impel

52 ngly recognized as important contributors to cardiovascular risk and provide an opportunity for advan

53 contemporary estimates of sex disparities in cardiovascular risk and risk factor management are neede

54 ifferences and dissociation between baseline cardiovascular risk and subsequent cardiovascular events

55 portance of prompt and regular monitoring of cardiovascular risk and use of primary prevention treatm

56 d an increased risk of myeloid malignancies, cardiovascular risk, and all-cause mortality.

57 etes mellitus (T1DM) substantially increases cardiovascular risk, and hypertension amplifies this ris

58 sease (CHD) are individually associated with cardiovascular risk, and Lp(a) is commonly measured in t

59 es inflammation, potentially contributing to cardiovascular risk, and may thus point to novel biomark

60 Ideally, treatment would improve IR, reduce cardiovascular risk, and produce demonstrable improvemen

61 potential mechanisms that lead to increased cardiovascular risk are described, and measures to reduc

62 and environmental determinants that increase cardiovascular risk are known, and collectively, are as

63 Transiently heightened cardiovascular risk around the 2016 election may be attr

64 he trial was designed to rule out 80% excess cardiovascular risk as compared with placebo (noninferio

65 This review summarizes evidence regarding cardiovascular risk assessment prior to noncardiac surge

66 Preoperative cardiovascular risk assessment requires a focused histor

67 obstetrical and gynecological history during cardiovascular risk assessment, and provide a framework

68 tailed guidelines are available that discuss cardiovascular risk assessment, lifestyle management, an

69 should consider measuring eGFRcys as part of cardiovascular risk assessment.

70 Cox models were used to assess cardiovascular risk associated with levels of risk facto

71 is an unmet clinical need to reduce residual cardiovascular risk attributable to apolipoprotein B-con

72 and the procedural risks weighed against the cardiovascular risk attributable to the elevated blood p

73 REPRIEVE enrolled PWH with low to moderate cardiovascular risk based on traditional risk factors to

74 ular risk factors and increased awareness of cardiovascular risk before, during, and after treatment

75 eting to <130/80 mm Hg only in those at high cardiovascular risk, but always considering individual t

76 a significantly higher relative increase in cardiovascular risk, but ongoing sex disparities in pres

77 n-3, or no carotid plaque had remarkable low cardiovascular risk, calling into question the appropria

78 and with linearly weighted kappa values for cardiovascular risk categories (Agatston score; cardiova

79 H)17 cell-related and atherosclerosis and/or cardiovascular risk (CCL7, FGF21, and IGFBP1) proteins,

80 risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries ac

81 increases aortic stiffness, contributing to cardiovascular risk even in healthy individuals.

82 sis and management of hypertension, a common cardiovascular risk factor among the general population,

83 with hydrochlorothiazide, without any other cardiovascular risk factor and with neither personal nor

84 Most patients (79.2%) had >=1 cardiovascular risk factor at baseline, in addition to m

85 E/VCO2(nadir)) were directly associated with cardiovascular risk factor burden (smoking, Framingham c

86 fication of pathways contributing to greater cardiovascular risk factor burden.

87 asure the cardiovascular risk management and cardiovascular risk factor outcomes of the health check

88 in patients treated to optimal contemporary cardiovascular risk factor targets, indicating that the

89 al studies, age is the single most important cardiovascular risk factor that dwarfs the impact of tra

90 Mixed effect models were used to compare cardiovascular risk factor trajectories for women accord

91 allopurinol, and had at least one additional cardiovascular risk factor.

92 particulate matter exposure is a modifiable cardiovascular risk factor.

93 ression analysis controlling for traditional cardiovascular risk factors (CVRF) performed to assess f

94 CI, 1.29-4.78) after adjusting for age, sex, cardiovascular risk factors (hypertension, hypercholeste

95 FAPI signals correlated with the presence of cardiovascular risk factors (odds ratio [OR], 4.3, P=0.0

96 1; 95% confidence interval [CI], 1.30-8.92), cardiovascular risk factors (OR, 5.05; 95% CI, 1.90-13.3

97 ty was significantly higher in patients with cardiovascular risk factors (overweight [OR, 2.6, P=0.02

98 e frequently observed in patients with known cardiovascular risk factors (P<0.0001).

99 tions between atlas principal components and cardiovascular risk factors (smoking, diabetes, high blo

100 rtunately, current interventions that target cardiovascular risk factors (such as anti-hypertensive d

101 case scenario to examine female sex-specific cardiovascular risk factors across the lifespan and desc

102 ars were not associated with lower levels of cardiovascular risk factors among offspring when they we

103 ion models adjusted for age, sex, education, cardiovascular risk factors and APOE epsilon4 status.

104 Traditional cardiovascular risk factors and calcification activity i

105 y and secondary prevention cohorts, compared cardiovascular risk factors and care between rural and u

106 r environmental factors, and to test whether cardiovascular risk factors and CHD are likely to be cau

107 usly preeclamptic women have more modifiable cardiovascular risk factors and develop CAC ~5 years ear

108 ociations of progression rates with baseline cardiovascular risk factors and estimated 10-year risk.

109 ed in this study, correlated with almost all cardiovascular risk factors and estimated risk.

110 ased diets are associated with lower risk of cardiovascular risk factors and incident cardiovascular

111 Optimization of cardiovascular risk factors and increased awareness of c

112 F subtypes, after adjustment for traditional cardiovascular risk factors and interval incidence of my

113 High signal intensities correlate with cardiovascular risk factors and metabolic disease.

114 MR analyses with cardiovascular risk factors and outcomes as well as othe

115 Further MR analyses with cardiovascular risk factors and outcomes showed relation

116 and remained significant after adjusting for cardiovascular risk factors and psoriasis severity (beta

117 risk biomarker is independent of traditional cardiovascular risk factors and unaffected by antiplatel

118 The prevalence of cardiovascular risk factors as well as cardiovascular an

119 myocardial injury were younger and had fewer cardiovascular risk factors but had more noncardiovascul

120 ut oil consumption on blood lipids and other cardiovascular risk factors compared with other cooking

121 adults experience disparities across several cardiovascular risk factors compared with their cisgende

122 activity and improving diet on intermediate cardiovascular risk factors depending on individual CAD

123 How their cardiovascular risk factors develop across the life cour

124 ine characteristics or strata of traditional cardiovascular risk factors did not show relevant differ

125 ACHD-exposed individuals with <=2 cardiovascular risk factors had a 29% age-adjusted incid

126 centrations, but beneficial effects on other cardiovascular risk factors have also been suggested.

127 tablish whether differences in treatment and cardiovascular risk factors have been maintained and to

128 sease, such as the high rates of traditional cardiovascular risk factors in patients with HIV infecti

129 C was associated with psoriasis severity and cardiovascular risk factors in psoriasis.

130 ay be explained by the younger age and fewer cardiovascular risk factors in smokers compared with non

131 With the notable exception of heart rate, cardiovascular risk factors must now be defined by 2 com

132 Cardiovascular risk factors of hypertension (35.8%), hyp

133 en accounting for the effects of traditional cardiovascular risk factors on atrial fibrillation.

134 n the potential composite effect of multiple cardiovascular risk factors on cognition, we examined th

135 as a biomarker that tracks the influence of cardiovascular risk factors on white matter prior to eme

136 s with typical angina and either two or more cardiovascular risk factors or a positive exercise tread

137 on between breast arterial calcification and cardiovascular risk factors or coronary artery disease,

138 ustained reductions in glycaemia and related cardiovascular risk factors over 10 years among people w

139 Adults with other known modifiable cardiovascular risk factors such as abnormal blood gluco

140 nd is accompanied by an increasing burden of cardiovascular risk factors such as hypertension.

141 method and show stronger relationships with cardiovascular risk factors than mass and volume.

142 dels adjusted for HDL cholesterol levels and cardiovascular risk factors to estimate odds ratios (ORs

143 s that might account for the contribution of cardiovascular risk factors to the most severe outcomes

144 usion Except for smoking, traditional common cardiovascular risk factors were associated with a highe

145 ure, and extensive STEMI, while male sex and cardiovascular risk factors were associated with decreas

146 r preeclampsia and to what extent modifiable cardiovascular risk factors were associated.

147 ad either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1)

148 After adjustment for 12 measured cardiovascular risk factors, ACHD remained strongly asso

149 calibration were tested for five models: the Cardiovascular Risk Factors, Aging and Dementia risk sco

150 included 1,449 participants from the Finnish Cardiovascular Risk Factors, Aging, and Dementia (CAIDE)

151 we investigated the relationship between the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE)

152 ge, sex, living alone, education, lifestyle, cardiovascular risk factors, and baseline Questionnaire

153 tegies (healthy lifestyles, modifications to cardiovascular risk factors, and educational and screeni

154 vity C-reactive protein (hsCRP), traditional cardiovascular risk factors, and the CD4/CD8 T-cell rati

155 evalence secondary to advanced maternal age, cardiovascular risk factors, and the successful manageme

156 Here, we review interactions between SVD and cardiovascular risk factors, and we discuss the evidence

157 he association between being transgender and cardiovascular risk factors, as well as myocardial infar

158 I, patients with UMI had a similar burden of cardiovascular risk factors, but significantly lower lef

159 We measured cardiovascular risk factors, CAC by coronary computed to

160 racteristics (renal and cardiac involvement, cardiovascular risk factors, cardiac complications, BAD)

161 I adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics an

162 e adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics, a

163 Cardiovascular risk factors, CVD, and associated deaths

164 With surveillance (n = 3,332), cardiovascular risk factors, CVD, and cardiovascular dea

165 ar events, mortality, subjective well-being, cardiovascular risk factors, diet and physical activity

166 edian 6 versus 8), and a lower prevalence of cardiovascular risk factors, except for a higher prevale

167 on, self-rated health, drug and alcohol use, cardiovascular risk factors, experience of sexual violen

168 After adjustment for cardiovascular risk factors, family history of AF was as

169 wly diagnosed type 2 diabetes and additional cardiovascular risk factors, glycated haemoglobin of up

170 In analyses adjusted for cardiovascular risk factors, GRS was significantly assoc

171 istics related to heart disease, stroke, and cardiovascular risk factors, including core health behav

172 y syndrome (PCOS) is a complex syndrome with cardiovascular risk factors, including obesity and insul

173 ng cardiovascular disease and/or traditional cardiovascular risk factors, including obesity, diabetes

174 den, even after comprehensive adjustment for cardiovascular risk factors, medications, and establishe

175 We recorded cardiovascular risk factors, medications, and indication

176 After adjusting for age, gender, and cardiovascular risk factors, only mean oxygen saturation

177 Additional effects of established cardiovascular risk factors, organ involvement and treat

178 rtality after adjustment for demographic and cardiovascular risk factors, overall and stratified by d

179 clinical model (CM) composed of conventional cardiovascular risk factors, showing an IDI of 0.047 and

180 After further adjustment for relevant cardiovascular risk factors, the late heart-to-mediastin

181 usions are associated with increased age and cardiovascular risk factors, their pathophysiology, syst

182 rdiovascular diseases, which share classical cardiovascular risk factors.

183 re type, treatment indication, age, sex, and cardiovascular risk factors.

184 years, which persisted after adjustment for cardiovascular risk factors.

185 controls for MPN type, driver mutations and cardiovascular risk factors.

186 and improved management of blood glucose and cardiovascular risk factors.

187 el use, apart from adjusting for traditional cardiovascular risk factors.

188 g osteopontin adds moderately to traditional cardiovascular risk factors.

189 ion that was unaccounted for by conventional cardiovascular risk factors.

190 young American Indians with a low burden of cardiovascular risk factors.

191 failure outcomes independent of traditional cardiovascular risk factors.

192 y for management of blood pressure and other cardiovascular risk factors.

193 with cisgender men, even after adjusting for cardiovascular risk factors.

194 events after adjusting for demographics and cardiovascular risk factors.

195 n between CAVS, coronary artery disease, and cardiovascular risk factors.

196 1.03 to 1.20; p = 0.006) after adjusting for cardiovascular risk factors.

197 ned using Cox regression models adjusted for cardiovascular risk factors.

198 d apoB concentrations and other conventional cardiovascular risk factors.

199 xamined the simultaneous trends in important cardiovascular risk factors.

200 ence of, or in addition to, well-established cardiovascular risk factors.

201 notypes vary according to sex, age and major cardiovascular risk factors.

202 or age, sex, education, diabetes status, and cardiovascular risk factors.

203 ion models adjusted for sociodemographic and cardiovascular risk factors.

204 ion after adjustment for CRF and traditional cardiovascular risk factors.

205 ntrolling for traditional and nontraditional cardiovascular risk factors.

206 cs, lifestyle factors and co-morbidities and cardiovascular risk factors/diseases were included.

207 Objectives: To evaluate the effect of OSA on cardiovascular risk for patients with different ACS phen

208 glucose may be a marker of the population at cardiovascular risk, further studies are required.

209 oil in statin-treated participants with high cardiovascular risk, hypertriglyceridemia, and low level

210 such as dietary AGE restriction, may reduce cardiovascular risk in CKD, but this requires testing in

211 9, ANGPTL4 and CETP in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial

212 among participants of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

213 increased mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

214 CVD events in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study depended on Hp ph

215 ) and the ACCORD BP trial (Action to Control Cardiovascular Risk in Diabetes-Blood Pressure; n=4733)

216 esent study was to evaluate if the increased cardiovascular risk in migraineurs is attributed to an i

217 le of intestinal phosphate binders to reduce cardiovascular risk in patients with CKD who have normop

218 elial repair capacity contribute to the high cardiovascular risk in patients with type 2 diabetes (T2

219 fection and immunity are linked to increased cardiovascular risk in people living with HIV infection.

220 ed to quantify glucocorticoid dose-dependent cardiovascular risk in people with 6 immune-mediated inf

221 model of psoriasis to investigate PCSK9 and cardiovascular risk in psoriasis.

222 ationale to target IL-1 activation to reduce cardiovascular risk in PWH.

223 ed ventilatory efficiency is associated with cardiovascular risk in the community and with adverse he

224 Early prediction of cardiovascular risk in the general population remains an

225 red incipient atherosclerosis and heightened cardiovascular risk in the SIV-infected HFD-receiving no

226 L properties may contribute to the increased cardiovascular risk in this population.

227 ributing to nonalcoholic steatohepatitis and cardiovascular risk in type 2 diabetes.

228 ars at baseline (1980) from the longitudinal Cardiovascular Risk in Young Finns Study.

229 cognitive function, leveraging data from the Cardiovascular Risk in Young Finns Study.

230 which is analogous to human athletes and the cardiovascular risks in both species are similar.

231 d Rap1-lEVs levels correlated with increased cardiovascular risks, including stenosis.

232 Cardiovascular risk increases dramatically with age, lea

233 ut-of-office BP is associated with increased cardiovascular risk independent of office BP.

234 thnic population differences because, whilst cardiovascular risk indices were increased for both PCOS

235 This study investigated whether cardiovascular risk is conferred by Lp(a) molar concentr

236 The attribute of Lp(a) that affects cardiovascular risk is not established.

237 Other studies allowed to clarify that the cardiovascular risk is not limited to COX-2 selective bu

238 Human Immunodeficiency VirRus and INcreased Cardiovascular RisK) is a randomized, double-blind, mult

239 of NSAIDs, even among people with underlying cardiovascular risks, is largely unsupervised and varies

240 In overweight or obese subjects at high cardiovascular risk, levels of triglycerides and remnant

241 This research aimed to measure the cardiovascular risk management and cardiovascular risk f

242 emic stroke shares many common elements with cardiovascular risk management in other fields, includin

243 rtality calls for further intensification of cardiovascular risk management, and a critical appraisal

244 on of EVAR and implementation of intensified cardiovascular risk management.

245 posed as a noninvasive and easily-obtainable cardiovascular risk marker, however, with limited prospe

246 s was associated with depression and several cardiovascular risk markers at baseline.

247 graphic and clinical characteristics such as cardiovascular risk markers.

248 ase has long been associated with heightened cardiovascular risk, much is still unknown regarding its

249 In diabetic patients at low cardiovascular risk, no treatment differs from placebo f

250 The long-term cardiovascular risk of isolated elevated office blood pr

251 ease a warning statement about the potential cardiovascular risks of testosterone replacement therapy

252 ituents in water pipe smoke, to document the cardiovascular risks of water pipe use, to review curren

253 often of young adult populations, to assess cardiovascular risk or to detect the presence of disease

254 he gut microbiome may be warranted to reduce cardiovascular risk, particularly in individuals with pr

255 ure to these drugs may constitute a distinct cardiovascular risk population.

256 ic sites, multiple-site atherosclerosis, and cardiovascular risk prediction is incompletely understoo

257 ing tool for cardiovascular events, enabling cardiovascular risk prevention through national initiati

258 To date, although a less favorable cardiovascular risk profile for Diclofenac as compared t

259 ssue bank, with patients stratified by their cardiovascular risk profile for structural remodeling.

260 both populations, PCOS women showed a worse cardiovascular risk profile of increased systolic and di

261 involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not

262 All patients had a similar cardiovascular risk profile, so that the risk for corona

263 Our findings point to different cardiovascular risk profiles in mothers of SGA versus LG

264 Although disease progression correlated with cardiovascular risk, progression was detected in 36.5% o

265 ubtypes are reproducible and associated with cardiovascular risk, providing important evidence of the

266 In patients at increased cardiovascular risk receiving metformin-based background

267 In patients at increased cardiovascular risk receiving metformin-based background

268 In patients at low cardiovascular risk receiving metformin-based background

269 Optimal management of CKD includes cardiovascular risk reduction (eg, statins and blood pre

270 Management includes cardiovascular risk reduction and use of antiplatelet th

271 (Cardiovascular Risk Reduction Study [Reduction in Recurr

272 The magnitude of the cardiovascular risk reduction was comparable with the be

273 (TG) levels form the cornerstone approach of cardiovascular risk reduction, and a higher high-density

274 onventional paradigms for assessing clinical cardiovascular risk remains unclear.

275 nuation plaque burden correlated weakly with cardiovascular risk score (r=0.34; P<0.001), strongly wi

276 r mean fasting plasma glucose and 0.9% lower cardiovascular risk score at follow-up.

277 T2D, and changes in blood glucose levels and cardiovascular risk score between individuals registered

278 n plaque burden (% plaque to vessel volume), cardiovascular risk score, coronary artery calcium score

279 .34) per doubling; P=0.014), irrespective of cardiovascular risk score, coronary artery calcium score

280 h higher levels indicating more ICH and less cardiovascular risk (score range, 0-7).

281 ing the association between baseline 10-year cardiovascular risk scores and cognitive function (measu

282 Cardiovascular risk scores may help to identify PLWH, es

283 ardial infarction is commonly assessed using cardiovascular risk scores, coronary artery calcium scor

284 t developments in adipose tissue imaging for cardiovascular risk stratification and discuss how thera

285 tibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial demonstrated that ev

286 d intima-media thickness progression in high-cardiovascular risk subjects.

287 addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a

288 Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compare

289 elatively early type 2 diabetes and elevated cardiovascular risk, the use of linagliptin compared wit

290 EN-PESA assigned an intermediate to high cardiovascular risk to 40.1% (n = 1,411) of the PESA ind

291 mized 10,142 participants with T2DM and high cardiovascular risk to canagliflozin or placebo.

292 estigation into management and mechanisms of cardiovascular risk unique to this growing population of

293 The mean estimated 10-year cardiovascular risk was 12.7%, the baseline blood pressu

294 Baseline cardiovascular risk was estimated using the American Hea

295 ing the unproven claim that the drug reduced cardiovascular risk was similar among those randomized t

296 ADER trial, 9,340 patients with T2D and high cardiovascular risk were assigned 1:1 to liraglutide (1.

297 and joint associations of Lp(a) and FHx with cardiovascular risk were determined using Cox regression

298 ted hemoglobin of 6.5% to 8.5%, and elevated cardiovascular risk were eligible for inclusion.

299 Patients with LVNC carry a similar cardiovascular risk when compared with dilated cardiomyo

300 LBP may be a marker of cardiovascular risk with utility in HIV.